Register to watch this free webinar on-demand. A link to watch the recording will then be emailed to you shortly after registration.
"In this masterclass, four experts working with MEG in brain tumor patients will outline the latest insights on the field. Their lecture spans from sharing an overview of what doing MEG in these patients entails, to the broader scientific scope of measuring brain activity in the neuro-oncological setting, to the state-of-the-art application of MEG in the clinical contexts of tumor growth and cognitive decline. On the data analysis side, they share how MEG can be used to interrogate local brain activity, to regional connectivity, to large-scale brain network topology, all within the scientific and clinical context of neuro-oncology."
Arjan Hillebrand is a physicist with nearly 30 years of experience with MEG. He currently manages the MEG center at Amsterdam UMC, where his research focuses on the development and application of methods to study dynamical networks in a range of neurological conditions, including brain tumors.
Linda Douw was trained as a clinical neuropsychologist, and has worked on MEG in brain tumor patients since the start of her PhD in 2007. She currently leads the Multiscale Network Neuroscience (MULTINET) lab at Amsterdam UMC, which aims to connect cells, networks and interventions to improve brain tumor patient outcomes.
Mona Zimmermann is a PhD candidate in the MULTINET lab. In her work, Mona investigates the use of MEG-based brain activity as a biomarker for tumor progression in glioma patients. To do so, she uses different techniques such as network neuroscience to conceptualize the neurophysiology of these patients.
Marike van Lingen has a background in Neurosciences and works as Lab Manager in the MULTINET lab since 2022. She coordinates a study on cognition in glioma using multiple imaging modalities, including MEG, to look at brain network alterations before and after tumor treatment.
*MEGIN does not endorse any applications or treatments mentioned at this event. TRIUX™ neo is intended for use as a magnetoencephalographic (MEG) device that non-invasively detects and displays biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhances the diagnostic capability by providing useful information about the location relative to the brain anatomy of active nerve tissue responsible for critical brain functions. All other applications are research in nature.
*By submitting your information to register for a Masterclass, MEGIN will use it to communicate with you regarding this event and other services.